Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma

Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was...

Descripción completa

Detalles Bibliográficos
Autores: Richardson, Paul G.|||0000-0002-7426-8865, Schjesvold, Fredrik|||0000-0003-1096-0569, Weisel, Katja, Moreau, Philippe|||0000-0003-1780-8746, Anderson, Larry D., White, Darrell, Rodriguez-Otero, Paula|||0000-0001-5236-7785, Sonneveld, Pieter|||0000-0002-0808-2237, Engelhardt, Monika|||0000-0003-0405-1676, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Beksac, Meral, Oriol, Albert|||0000-0001-6804-2221, Lindsay, Jindriska, Liberati, Anna Marina, Galli, Mónica, Robak, Pawel, Larocca, Alessandra|||0000-0002-2070-3702, Yagci, Munci, Vural, Filiz, Kanate, Abraham, Jiang, Ruiyun, Grote, Lara, Peluso, Teresa, Dimopoulos, Meletios|||0000-0001-8990-3254
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:289540
Acceso en línea:https://ddd.uab.cat/record/289540
https://dx.doi.org/urn:doi:10.1111/ejh.13706
Access Level:acceso abierto
Palabra clave:Aged
Chromosome aberrations
Multiple myeloma
Pomalidomide
Renal insufficiency
Descripción
Sumario:Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS). Results: Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P =.0258) and.

Similares en LA Referencia